Dr. Jarrod Shilts
R&D Lead Scientist
Trained both as a scientist and an engineer, Jarrod lives and breathes building new technologies. As the R&D Lead Scientist for ExpressionEdits, he is responsible for setting up the company’s experimental platforms and investigating how to bring our research into new areas.
Bio
Jarrod received his undergraduate degree at Vanderbilt University in the USA, completing an interdisciplinary program spanning molecular biology, liberal arts, bioengineering, and scientific computing, publishing multiple first-author research papers in the process.He obtained his MPhil and Ph.D degrees from Cambridge University, working at the Wellcome Sanger Institute with Prof. Gavin Wright. There, he developed a passion for the potential of protein engineering and high-throughput recombinant protein experiments, inventing a new technique to 10x scale-up receptor screening, predicting immune cell behavior from biophysical principles, and setting up a streamlined custom-programmed robotics pipeline. That work enabled the discovery of new immunotherapy targets, pathogen vaccine candidates, and viral susceptibility factors. His research contributions have been published in the journal Nature, recognized by the Protein Society, and led to multiple awards and scholarships.To ExEd, he is bringing a valuable toolkit of experiences as the company tackles reinventing transgene expression.
Trained both as a scientist and an engineer, Jarrod lives and breathes building new technologies. As the R&D Lead Scientist for ExpressionEdits, he is responsible for setting up the company’s experimental platforms and investigating how to bring our research into new areas.
Bio
Jarrod received his undergraduate degree at Vanderbilt University in the USA, completing an interdisciplinary program spanning molecular biology, liberal arts, bioengineering, and scientific computing, publishing multiple first-author research papers in the process.He obtained his MPhil and Ph.D degrees from Cambridge University, working at the Wellcome Sanger Institute with Prof. Gavin Wright. There, he developed a passion for the potential of protein engineering and high-throughput recombinant protein experiments, inventing a new technique to 10x scale-up receptor screening, predicting immune cell behavior from biophysical principles, and setting up a streamlined custom-programmed robotics pipeline. That work enabled the discovery of new immunotherapy targets, pathogen vaccine candidates, and viral susceptibility factors. His research contributions have been published in the journal Nature, recognized by the Protein Society, and led to multiple awards and scholarships.To ExEd, he is bringing a valuable toolkit of experiences as the company tackles reinventing transgene expression.
Trained both as a scientist and an engineer, Jarrod lives and breathes building new technologies. As the R&D Lead Scientist for ExpressionEdits, he is responsible for setting up the company’s experimental platforms and investigating how to bring our research into new areas.
Bio
Jarrod received his undergraduate degree at Vanderbilt University in the USA, completing an interdisciplinary program spanning molecular biology, liberal arts, bioengineering, and scientific computing, publishing multiple first-author research papers in the process.He obtained his MPhil and Ph.D degrees from Cambridge University, working at the Wellcome Sanger Institute with Prof. Gavin Wright. There, he developed a passion for the potential of protein engineering and high-throughput recombinant protein experiments, inventing a new technique to 10x scale-up receptor screening, predicting immune cell behavior from biophysical principles, and setting up a streamlined custom-programmed robotics pipeline. That work enabled the discovery of new immunotherapy targets, pathogen vaccine candidates, and viral susceptibility factors. His research contributions have been published in the journal Nature, recognized by the Protein Society, and led to multiple awards and scholarships.To ExEd, he is bringing a valuable toolkit of experiences as the company tackles reinventing transgene expression.
→